HUMA vs CBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 20, 2026

HUMA

55.4
AI Score
VS
HUMA Wins

CBIO

54.3
AI Score

Investment Advisor Scores

HUMA

55score
Recommendation
HOLD

CBIO

54score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric HUMA CBIO Winner
Revenue 901,000 1.04M CBIO
Net Income -54.42M -48.12M CBIO
Net Margin -6040.1% -4631.4% CBIO
Operating Income -55.93M -51.09M CBIO
ROE -174.1% -29.5% CBIO
ROA -39.4% -26.3% CBIO
Total Assets 138.09M 182.76M CBIO
Cash 79.90M 171.59M CBIO
Current Ratio 6.21 9.66 CBIO
Free Cash Flow -47.44M -28.56M CBIO

Relative Price Performance (Last 90 Days)

HUMA 1M: +27.1% · 3M: -0.4% CBIO 1M: +13.4% · 3M: -19.1%

Current Technical Phase

HUMA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 59

RSI (14): 59.4 · Price: $0.56

CBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 52

RSI (14): 52.4 · Price: $14.15

Fundamentals Snapshot

Metric HUMA CBIO
Market Cap — —
Forward P/E -2.1 -5.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.4% 0.0%
Gross Margin -10.6% 1.0%
Operating Margin -45.7% -14.3%
EPS -0.45 -7.63
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HUMA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.